Rachelle Buchbinder, MBBS(Hons), MSc; Andrew Forbes, PhD; Stephen Hall, MBBS(Hons), BMedSci; Xenia Dennett, PhD; Graham Giles, PhD, MSc
Grant Support: By a grant from the Arthritis Foundation of Australia.
Requests for Single Reprints: Rachelle Buchbinder, MBBS (Hons), MSc, Suite 41, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144; e-mail, email@example.com.
Current Author Addresses: Dr. Buchbinder: Department of Clinical Epidemiology, Suite 41, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144.
Dr. Forbes: Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital Campus, Commercial Road, Prahran, Victoria, Australia 3181.
Dr. Hall: Suite 43, Cabrini Medical Centre, 183 Wattletree Road, Malvern, Victoria, Australia 3144.
Dr. Dennett: State Neuropathology Service, Department of Pathology, University of Melbourne, Parkville, Victoria, Australia 3010.
Dr. Giles: Cancer Epidemiology Centre and Victorian Cancer Registry, Cancer Control Research Institute of the Anti-Cancer Council of Victoria, 100 Drummond Street, Carlton South, Victoria, Australia 3053.
Author Contributions: Conception and design: R. Buchbinder, A. Forbes, S. Hall.
Analysis and interpretation of the data: R. Buchbinder, A. Forbes.
Drafting of the article: R. Buchbinder, A. Forbes.
Critical revision of the article for important intellectual content: R. Buchbinder, A. Forbes, S. Hall, X. Dennett, G. Giles.
Final approval of the article: R. Buchbinder, X. Dennett, G. Giles.
Provision of study materials or patients: R. Buchbinder, X. Dennett, G. Giles.
Statistical expertise: A. Forbes.
Obtaining of funding: R. Buchbinder.
Administrative, technical, or logistic support: R. Buchbinder, G. Giles.
Collection and assembly of data: R. Buchbinder, X. Dennett, G. Giles.
The validity and magnitude of an association between myositis and malignant disease continue to be debated. Such issues as the legitimacy of a myositis diagnosis and distinction among myositis subgroups in previous population-based studies remain unresolved.
To determine the risk for malignant disease in patients with biopsy-proven inflammatory myopathies.
Population-based, retrospective cohort study.
537 patients in whom a biopsy-positive idiopathic inflammatory myopathy was first diagnosed from 1981 through 1995.
Standardized incidence ratios were calculated to compare the incidence of malignant disease in patients with inflammatory myopathy and the general population.
A total of 116 cases of malignant disease were found in 104 patients. Seventy-four cases were identified concurrently with (within 7 days) or after diagnosis of myositis. The highest risk for malignant disease was associated with dermatomyositis (standardized incidence ratio, 6.2 [95% CI, 3.9 to 10.0]). The risk was also increased in polymyositis (standardized incidence ratio, 2.0 [CI, 1.4 to 2.7]), although the relative risk for malignant disease in dermatomyositis compared with polymyositis was 2.4 (CI, 1.3 to 4.2). An increased risk for malignant disease was also found in inclusion-body myositis (standardized incidence ratio, 2.4 [CI, 1.2 to 4.9]). The excess risk for malignant disease diminished with time (standardized incidence ratio, 4.4 [CI, 2.7 to 7.1] in the first year; 3.4 [CI, 2.3 to 5.1] between 1 and 3 years; 2.2 [CI, 1.3 to 3.9] between 3 and 5 years; and 1.6 [CI, 1.0 to 2.6] beyond 5 years [P for trend, 0.002]).
The risk for malignant disease is increased in biopsy-proven dermatomyositis and polymyositis and also appears to be increased in inclusion-body myositis.
Buchbinder R, Forbes A, Hall S, et al. Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study. Ann Intern Med. 2001;134:1087–1095. doi: 10.7326/0003-4819-134-12-200106190-00008
Download citation file:
Published: Ann Intern Med. 2001;134(12):1087-1095.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use